As compared to healthy individuals, BMFL1-specific CD8 T cells from melanoma patients showed more advanced effector cell differentiation with increased percentages of EM28neg (defined as CCR7negCD45RAnegCD28neg) and EMRA (defined as CCR7negCD45RAposCD28neg) subsets already before treatment (i.e. at the time of leukapheresis) (Figure 1C; right panel). This evidence concerns the gene CD8A and melanoma.